Importantly, this treatment strategy was more effective than anti-CD19 CAR-T cell treatment, and effectively eliminated secondary lymphoma, indicating that anti-CD19 CAR-NKT cells may provide better therapeutic outcomes than traditional CAR-T cells [111]. The gene discussed is CD19; the disease is lymphoma.